Polycystic Ovarian Disease (PCOD): A Comprehensive Review

Polycystic ovarian disease (PCOD), often interchangeably referred to in the literature as Polycystic Ovary Syndrome, represents one of the most common and complex endocrine-metabolic disorders affecting women during their reproductive years. It is characterized by a constellation of reproductive, endocrine, metabolic, and psychological abnormalities, including chronic anovulation, menstrual irregularities, hyperandrogenism, polycystic ovarian morphology, obesity, insulin resistance, infertility, and emotional disturbances. The condition is considered a heterogeneous syndrome due to the wide variation in clinical manifestations, severity, and long-term complications among affected individuals. This heterogeneity makes diagnosis and management particularly challenging for clinicians and researchers. The syndrome was first described in 1935 by Irving F. Stein Sr. and Michael L. Leventhal, who reported a series of women presenting with amenorrhea, infertility, and enlarged polycystic ovaries, subsequently termed Stein-Leventhal syndrome. Since this initial description, scientific understanding of the disorder has evolved substantially. What was once regarded as a purely gynecological condition is now recognized as a multisystem endocrine and metabolic disorder with lifelong implications extending beyond reproductive health. Globally, PCOD affects approximately 6–20% of women of reproductive age depending on the diagnostic criteria applied, such as the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine Rotterdam criteria, the National Institutes of Health criteria, or the Androgen Excess and PCOS Society criteria [3]. The prevalence appears to be particularly high in South Asian populations, including India, where rapid urbanization, sedentary lifestyles, altered dietary patterns, and genetic susceptibility contribute significantly to disease incidence. The increasing prevalence among adolescent girls has emerged as a major public health concern due to its potential impact on future fertility and metabolic health. The pathophysiology of PCOD is multifactorial and incompletely understood, involving intricate interactions between genetic, epigenetic, hormonal, metabolic, and environmental factors. Central to its pathogenesis is dysfunction of the hypothalamic-pituitary-ovarian (HPO) axis, which leads to increased secretion of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), promoting ovarian androgen overproduction. Hyperandrogenism disrupts normal follicular maturation and ovulation, resulting in the accumulation of immature follicles that appear as cysts on ultrasonography. Insulin resistance is another hallmark feature observed in a majority of women with PCOD, independent of obesity status. Hyperinsulinemia resulting from insulin resistance amplifies ovarian androgen synthesis and suppresses hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgen levels. This interaction between insulin resistance and hyperandrogenism establishes a vicious cycle that perpetuates disease progression. Additionally, chronic low-grade inflammation and oxidative stress have been implicated in the pathogenesis of PCOD, contributing to both reproductive and metabolic dysfunction.

2. Overview of Polycystic Ovarian Disease (PCOD)

Polycystic Ovarian Disease (PCOD) is a complex endocrine and metabolic disorder characterized by hormonal imbalance, ovarian dysfunction, and impaired ovulation. It primarily affects women during their reproductive years and is considered one of the leading causes of menstrual irregularities, infertility, and hyperandrogenism. The disorder results from abnormal ovarian function in which multiple immature follicles accumulate within the ovaries due to incomplete follicular maturation and failure of ovulation. These immature follicles appear as multiple small cyst-like structures on ultrasonographic examination, although they are not true pathological cysts. PCOD is regarded as a heterogeneous disorder because its clinical presentation varies considerably among affected individuals. Some women predominantly experience reproductive symptoms such as irregular menstruation and infertility, while others mainly exhibit metabolic abnormalities including obesity, insulin resistance, dyslipidemia, and impaired glucose tolerance. Dermatological manifestations such as acne, hirsutism, oily skin, and androgenic alopecia are also common due to excessive androgen production. The disorder develops through the interaction of multiple factors including genetic susceptibility, endocrine abnormalities, insulin resistance, environmental influences, and unhealthy lifestyle habits. Elevated androgen levels interfere with normal follicular development, preventing the release of mature ova from the ovaries. Simultaneously, insulin resistance and compensatory hyperinsulinemia further stimulate androgen production, creating a cycle that perpetuates hormonal imbalance and ovarian dysfunction. Normally, during each menstrual cycle, several ovarian follicles begin to mature under the influence of follicle-stimulating hormone (FSH). One dominant follicle eventually releases a mature ovum during ovulation. In women with PCOD, this maturation process is disrupted due to hormonal disturbances. As a result, ovulation either occurs infrequently or fails completely, causing immature follicles to accumulate around the ovarian cortex and giving the ovaries a characteristic "string of pearls" appearance on ultrasound imaging. PCOD not only affects reproductive health but also has significant metabolic and cardiovascular implications. Women with the condition have an increased risk of developing obesity, metabolic syndrome, hypertension, dyslipidemia, impaired glucose tolerance, type 2 diabetes mellitus, and cardiovascular diseases later in life. Chronic anovulation also increases the risk of endometrial hyperplasia and endometrial carcinoma due to prolonged exposure of the endometrium to unopposed estrogen. The disorder significantly impacts psychological well-being. Cosmetic concerns such as acne, obesity, excessive facial hair, and hair loss often lead to anxiety, depression, low self-esteem, emotional distress, and reduced quality of life. Infertility associated with chronic anovulation further contributes to psychological burden and social challenges in many affected women. Although PCOD and Polycystic Ovary Syndrome (PCOS) are frequently used interchangeably, they differ slightly in clinical interpretation. PCOD generally refers to ovarian dysfunction characterized by the presence of multiple immature follicles and hormonal imbalance, whereas PCOS is considered a broader endocrine syndrome involving reproductive, metabolic, and hormonal abnormalities. Nevertheless, both conditions share several clinical features and management strategies. The diagnosis of PCOD requires comprehensive clinical evaluation supported by laboratory investigations and imaging studies. Assessment includes menstrual history, physical examination, hormonal profiling, metabolic evaluation, and pelvic ultrasonography. Since symptoms may overlap with other endocrine disorders, differential diagnosis is essential to exclude conditions such as thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, and androgen-secreting tumors. Management of PCOD focuses on correcting hormonal imbalance, restoring ovulation, improving metabolic health, alleviating symptoms, and preventing long-term complications. Lifestyle modification, including weight reduction, regular physical activity, balanced nutrition, stress management, and adequate sleep, remains the cornerstone of therapy. Pharmacological treatment is individualized based on the patient's age, symptoms, reproductive goals, and associated metabolic abnormalities. As research continues to advance, greater understanding of the molecular and genetic mechanisms underlying PCOD has facilitated the development of targeted therapeutic approaches. Early diagnosis, multidisciplinary management, patient education, and regular follow-up are essential for improving both reproductive outcomes and overall long-term health.

3. Epidemiology and Global Burden of Polycystic Ovarian Disease (PCOD)

Polycystic Ovarian Disease (PCOD) is among the most prevalent endocrine disorders affecting women of reproductive age worldwide. It represents a significant public health challenge because of its high prevalence, chronic nature, reproductive consequences, metabolic complications, and psychosocial impact. The disorder affects women across all ethnicities, socioeconomic groups, and geographical regions, although its prevalence varies depending on the diagnostic criteria used and the characteristics of the study population. Globally, PCOD is estimated to affect approximately 6–20% of women of reproductive age. Variations in prevalence are attributed to differences in genetic background, ethnicity, environmental influences, dietary habits, obesity rates, lifestyle patterns, and diagnostic approaches. Urbanization, sedentary lifestyles, unhealthy dietary practices, and increasing obesity have contributed to a steady rise in the number of affected individuals over recent decades. The condition commonly develops during adolescence, often becoming apparent soon after menarche when menstrual cycles fail to become regular. However, many women remain undiagnosed until adulthood when they seek medical attention for infertility, menstrual irregularities, or cosmetic concerns. Delayed diagnosis is common because early symptoms may be mild, nonspecific, or mistakenly considered part of normal pubertal development. The prevalence of PCOD is generally higher among overweight and obese women compared with those having normal body weight. Excess adipose tissue worsens insulin resistance and hormonal imbalance, thereby increasing disease severity and associated metabolic complications. Nevertheless, lean women may also develop PCOD, indicating that obesity is an aggravating rather than a primary causative factor. Ethnic differences influence both the prevalence and clinical presentation of PCOD. Women from South Asian, Middle Eastern, Hispanic, and certain Mediterranean populations tend to exhibit a higher frequency of insulin resistance, central obesity, and metabolic syndrome compared with women from other populations. Such variations emphasize the importance of considering ethnicity during diagnosis and treatment planning. Beyond reproductive health, PCOD contributes substantially to the global burden of chronic non-communicable diseases. Women with the disorder have an increased lifetime risk of infertility, pregnancy-related complications, gestational diabetes mellitus, hypertension, type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, non-alcoholic fatty liver disease, obstructive sleep apnea, and endometrial disorders. These associated conditions increase healthcare utilization and long-term medical costs. The psychosocial burden of PCOD is equally significant. Depression, anxiety, stress, eating disorders, body image dissatisfaction, reduced self-confidence, and impaired quality of life are frequently reported among affected women. These psychological issues often coexist with reproductive and metabolic complications, highlighting the need for comprehensive multidisciplinary care. Increasing awareness, early screening of high-risk individuals, patient education, lifestyle intervention programs, and improved access to healthcare services are essential strategies for reducing the global burden of PCOD. Continued epidemiological research is necessary to better understand regional variations, identify emerging risk factors, and develop effective preventive and management strategies.

4. Etiology and Risk Factors of Polycystic Ovarian Disease (PCOD)

Polycystic Ovarian Disease (PCOD) is a multifactorial disorder that develops through the interaction of genetic, hormonal, metabolic, environmental, and lifestyle factors. Although the exact cause remains unknown, current evidence suggests that multiple mechanisms contribute to ovarian dysfunction, hyperandrogenism, insulin resistance, and chronic anovulation. These factors act synergistically, resulting in hormonal imbalance and the characteristic clinical manifestations of the disease.

4.1 Genetic Factors

Genetic predisposition plays an important role in the development of PCOD. Women with a family history of PCOD, type 2 diabetes mellitus, obesity, or metabolic syndrome have a higher likelihood of developing the disorder. Several genes involved in steroid hormone synthesis, insulin signaling, gonadotropin regulation, inflammation, and ovarian follicular development have been implicated. The inheritance pattern is considered polygenic, meaning that multiple genes collectively influence disease susceptibility. Genetic abnormalities may alter ovarian steroidogenesis, insulin receptor function, and androgen metabolism, predisposing susceptible individuals to hormonal disturbances. However, genetic predisposition alone is insufficient to cause PCOD, and environmental triggers are often required for disease expression.

4.2 Hormonal Imbalance

Hormonal dysregulation is the hallmark of PCOD. Increased secretion of luteinizing hormone (LH) stimulates excessive androgen production by ovarian theca cells. At the same time, relatively lower follicle-stimulating hormone (FSH) levels impair maturation of ovarian follicles, preventing normal ovulation. Elevated androgen concentrations inhibit follicular development and contribute to symptoms such as acne, hirsutism, androgenic alopecia, and menstrual irregularities. Increased insulin levels further enhance androgen production, thereby worsening endocrine dysfunction.

4.3 Insulin Resistance and Hyperinsulinemia

Insulin resistance is one of the most significant metabolic abnormalities associated with PCOD. Body tissues become less responsive to insulin, prompting the pancreas to produce higher amounts of insulin to maintain normal blood glucose levels. Hyperinsulinemia promotes ovarian androgen synthesis and suppresses hepatic production of sex hormone-binding globulin (SHBG), leading to increased circulating free testosterone. This hormonal imbalance contributes to anovulation, infertility, obesity, and metabolic syndrome. Insulin resistance may occur in both obese and lean women, although it is generally more severe in obese individuals.

4.4 Obesity and Lifestyle Factors

Obesity is not the primary cause of PCOD but significantly aggravates its clinical manifestations. Excess adipose tissue contributes to insulin resistance, chronic inflammation, hormonal imbalance, and increased androgen production. Central or abdominal obesity is particularly associated with metabolic complications. Lifestyle factors such as sedentary behavior, excessive consumption of calorie-rich processed foods, irregular eating habits, inadequate sleep, and psychological stress further increase the risk of developing PCOD and worsen disease severity. Regular physical activity and healthy dietary habits are therefore essential components of prevention and management.

4.5 Environmental Factors

Environmental exposures are increasingly recognized as contributing factors in PCOD. Exposure to endocrine-disrupting chemicals, environmental pollutants, pesticides, plastics containing bisphenol A (BPA), and certain industrial chemicals may interfere with normal hormonal regulation and ovarian function. Urbanization, changing dietary patterns, reduced physical activity, and chronic psychosocial stress have also been associated with the increasing prevalence of PCOD worldwide.

4.6 Chronic Low-Grade Inflammation

Women with PCOD frequently exhibit chronic low-grade systemic inflammation characterized by increased production of inflammatory cytokines and oxidative stress. Persistent inflammation interferes with insulin signaling, ovarian steroidogenesis, and follicular maturation. Inflammatory mediators contribute to endothelial dysfunction, cardiovascular risk, and metabolic disturbances while further aggravating insulin resistance and hyperandrogenism.

4.7 Oxidative Stress

Oxidative stress results from an imbalance between reactive oxygen species (ROS) and antioxidant defense mechanisms. Increased oxidative stress damages ovarian tissue, disrupts follicular development, impairs oocyte quality, and contributes to infertility. It also promotes insulin resistance and chronic inflammation, creating a vicious cycle that accelerates disease progression.

4.8 Psychological Stress

Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased cortisol secretion. Elevated cortisol influences glucose metabolism, appetite regulation, fat accumulation, and reproductive hormone secretion. Stress-related hormonal disturbances may worsen menstrual irregularities, ovulatory dysfunction, and metabolic abnormalities while negatively affecting treatment adherence and quality of life.

Figure 1. Etiology and Pathophysiological Mechanisms of Polycystic Ovarian Disease (PCOD): Integrated Overview of Genetic, Environmental, Metabolic, and Endocrine Factors

9.5 Prognosis

The prognosis of PCOD depends on the severity of symptoms, early diagnosis, adherence to treatment, and lifestyle modifications. Although PCOD cannot be completely cured, its symptoms and complications can be effectively controlled through appropriate management. Women who maintain a healthy body weight, engage in regular physical activity, follow a balanced diet, and receive timely medical treatment generally have better reproductive and metabolic outcomes. Advances in pharmacological therapy and assisted reproductive techniques have also improved fertility rates in women with PCOD. Regular follow-up is important to monitor menstrual function, metabolic health, cardiovascular risk factors, and psychological well-being. Long-term management helps reduce complications and improves overall quality of life.

10. Recent Advances and Future Perspectives in PCOD Management

Advances in research have significantly improved the understanding of the pathogenesis and management of Polycystic Ovarian Disease (PCOD). Recent studies emphasize personalized treatment approaches that consider individual hormonal profiles, metabolic status, reproductive goals, and lifestyle factors. Modern diagnostic techniques, novel pharmacological agents, and digital healthcare technologies are expected to improve disease management and patient outcomes.

10.1 Personalized Medicine

Personalized medicine is an emerging approach in PCOD management, where treatment is tailored according to the patient's clinical presentation, metabolic profile, and fertility requirements. Individualized therapy helps improve treatment effectiveness while minimizing adverse effects.

10.2 Advances in Pharmacological Therapy

Several newer therapeutic options are being explored to improve insulin sensitivity, reduce androgen levels, and promote ovulation.

Recent therapeutic approaches include:

• Improved insulin-sensitizing agents
• Inositol supplements (Myo-inositol and D-chiro-inositol)
• Glucagon-like peptide-1 (GLP-1) receptor agonists for obesity management
• Combination drug therapy for enhanced symptom control

These therapies show promising results, particularly in women with obesity and metabolic syndrome.

10.3 Role of Nutritional Supplements

Various nutritional supplements are being investigated as supportive therapies in PCOD.

Common supplements include:

• Vitamin D
• Omega-3 fatty acids
• Myo-inositol
• D-chiro-inositol
• Antioxidants

These supplements may help improve insulin sensitivity, ovarian function, and metabolic health when used alongside lifestyle modification.

10.4 Digital Health and Telemedicine

Digital healthcare technologies have improved long-term disease management by enabling remote consultation, symptom tracking, medication reminders, and lifestyle monitoring.

Mobile health applications and wearable devices can assist patients in monitoring:

• Menstrual cycles
• Body weight
• Physical activity
• Blood glucose levels
• Dietary habits

These technologies promote better treatment adherence and patient engagement.

10.5 Gut Microbiome Research

Recent evidence suggests that alterations in the gut microbiota may contribute to insulin resistance, chronic inflammation, and hormonal imbalance in PCOD. Modulation of the gut microbiome through diet, probiotics, and prebiotics is being explored as a potential therapeutic strategy, although further clinical studies are needed.

FUTURE PERSPECTIVES

Future research is focused on identifying reliable biomarkers for early diagnosis, understanding the genetic and molecular mechanisms of PCOD, and developing targeted therapies with improved efficacy and safety. Greater emphasis is also being placed on preventive strategies, early screening in high-risk individuals, and multidisciplinary care to improve long-term health outcomes.

CONCLUSION

Polycystic Ovarian Disease (PCOD) is a complex endocrine and metabolic disorder that affects multiple aspects of a woman's reproductive, metabolic, and psychological health. The disease is characterized by hormonal imbalance, insulin resistance, chronic anovulation, and hyperandrogenism, leading to menstrual irregularities, infertility, obesity, and various metabolic complications. Its multifactorial nature requires a comprehensive approach to diagnosis and management. Early identification of symptoms, appropriate diagnostic evaluation, and individualized treatment are essential for preventing long-term complications. Lifestyle modification remains the cornerstone of management, while pharmacological therapy, fertility treatment, and psychological support play important roles depending on the patient's clinical presentation and reproductive goals. Recent advances in personalized medicine, novel therapeutic agents, nutritional interventions, digital health technologies, and molecular research have expanded the possibilities for more effective and targeted management of PCOD. Continued research and increased awareness are expected to improve early diagnosis, optimize treatment strategies, and enhance the overall quality of life of affected women. A multidisciplinary approach involving healthcare professionals and active patient participation remains essential for achieving successful long-term outcomes.

REFERENCES

1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057. doi: 10.1038/nrdp.2016.57
2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi: 10.1093/humrep/dey256 (PMC)
3. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350 (OUP Academic)
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098
5. Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284. doi: 10.1038/nrendo.2018.24
6. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231. doi: 10.1038/nrendo.2010.217
7. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. Endocr Rev. 2012;33(6):981–1030. doi: 10.1210/er.2011-1034
8. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome. Hum Reprod. 2012;27(1):14–24. doi: 10.1093/humrep/der396
9. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: A position statement. Obes Rev. 2009;10(6):593–602. doi: 10.1111/j.1467-789X.2009. 00628.x
10. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697. doi: 10.1016/S0140-6736(07)61345-2
11. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Current guidelines for diagnosing polycystic ovary syndrome. Diagnostics (Basel). 2023;13(6):1113. doi: 10.3390/diagnostics13061113 (PMC)
12. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236. doi: 10.1056/NEJMra041536
13. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JSE, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487–525. doi: 10.1210/er.2015-1018
14. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Obes Rev. 2019;20(2):339–352. doi: 10.1111/obr.12762
15. Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018;89(3):251–268. doi: 10.1111/cen.13795
16. Costello MF, Misso ML, Balen A, Boyle J, Devoto L, Garad RM, et al. Evidence summaries and recommendations from the international evidence-based guideline for polycystic ovary syndrome. Hum Reprod Open. 2019;2019(4):hoz021. doi: 10.1093/hropen/hoz021
17. Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome. Hum Reprod. 2013;28(6):1555–1562. doi: 10.1093/humrep/det078
18. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–592. doi: 10.1093/humupd/dmv029
19. Teede HJ, Moran LJ, Joham AE. Polycystic ovary syndrome and lifestyle management. Clin Obstet Gynecol. 2014;57(1):93–109. doi: 10.1097/GRF.0000000000000015
20. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Polycystic ovarian syndrome: An updated overview. Front Physiol. 2016; 7:124. doi: 10.3389/fphys.2016.00124
21. Stener-Victorin E, Teede HJ, Norman RJ, Legro RS, Goodarzi MO, Dokras A, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024; 10:27. doi: 10.1038/s41572-024-00511-3. (Nature)
22. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Current guidelines for diagnosing polycystic ovary syndrome. Diagnostics (Basel). 2023;13(6):1113. doi: 10.3390/diagnostics13061113. (PMC)
23. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1–P29. doi: 10.1530/EJE-14-0253
24. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with PCOS. Fertil Steril. 2010;94(7):S16–S22. doi: 10.1016/j.fertnstert.2010.07.1079
25. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: Implications for pathogenesis and management. Clin Endocrinol (Oxf). 2019;90(3):367–379. doi: 10.1111/cen.13939
26.  Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–680. doi: 10.1016/S2213-8587(22)00163-2
27. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: A systematic review. Am J Clin Nutr. 2013;97(2):248–258. doi: 10.3945/ajcn.112.042166
28. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–637. doi: 10.1093/humupd/dms030
29. Dokras A. Mood and anxiety disorders in women with PCOS. Steroids. 2012;77(4):338–341. doi: 10.1016/j.steroids.2011.12.008
30. Cooney LG, Dokras A. Depression and anxiety in polycystic ovary syndrome: Etiology and treatment. Curr Psychiatry Rep. 2017;19(11):83. doi: 10.1007/s11920-017-0834-2
31. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod. 2011;26(9):2442–2451. doi: 10.1093/humrep/der197
32. Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with PCOS: A systematic review and meta-analysis. Endocrine. 2018;62(2):318–325. doi: 10.1007/s12020-018-1692-3. (PMC)
33. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online. 2006;12(5):542–551. doi: 10.1016/S1472-6483(10)61190-0
34. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;(7):CD007506. doi: 10.1002/14651858.CD007506.pub3
35. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Insulin-sensitising drugs versus placebo for women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD003053. doi: 10.1002/14651858.CD003053.pub3
36. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs for women with PCOS, oligo-amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053. doi: 10.1002/14651858.CD003053.pub5
37. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in PCOS. N Engl J Med. 2007;356(6):551–566. doi: 10.1056/NEJMoa063971
38. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome. Endocr Rev. 2009;30(1):1–50. doi: 10.1210/er.2008-0030
39.  Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of inositol(s) in women with PCOS: A systematic review. Int J Endocrinol. 2016; 2016:1849162. doi: 10.1155/2016/1849162
40. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in PCOS. Gynecol Endocrinol. 2012;28(12):969–973. doi: 10.3109/09513590.2012.705376
41. Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of polycystic ovarian syndrome in India: A systematic review and meta-analysis. Cureus. 2022;14(12):e32351. doi: 10.7759/cureus.32351. (PMC)
42. Maan P, Gautam R, Vasudevan S, Menon GR, Arora A, Nair A, et al. Pharmacological and non-pharmacological interventions for polycystic ovary syndrome (PCOS) in Indian women: A systematic review and meta-analysis. Pharmaceuticals (Basel). 2025;18(5):680. doi: 10.3390/ph18050680. (PubMed)
43. Rocha AL, Oliveira FR, Azevedo RC, Silva VA, Peres TM, Candido AL, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research. 2019;8:F1000 Faculty Rev-565. doi: 10.12688/f1000research.15318.
44. Gómez JMD, VanHise K, Stachenfeld N, Chan JL, Merz NB, Shufelt C. Subclinical cardiovascular disease and polycystic ovary syndrome. Fertil Steril. 2022;117(5):912–923. doi: 10.1016/j.fertnstert.2022.02.028
45. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90(8):4650–4658. doi: 10.1210/jc.2005-062
46. Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health care-related economic burden of polycystic ovary syndrome in the United States. J Clin Endocrinol Metab. 2022;107(3): e1071–e1080. doi: 10.1210/clinem/dgab762
47. Chan JL, Masini I, Pisarska MD. Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): Current and future trends. J Clin Invest. 2026;136(12): e202824. doi: 10.1172/JCI202824. (PubMed).